Abstract 146P
Background
To study the value of the ratio of the red blood cell distribution width (RDW) to the mean corpuscular volume (MCV) (RMR) in predicting the efficacy of adjuvant chemotherapy (AC) in residual gastric cancer (RGC).
Methods
A total of 379 patients who underwent resection for RGC at 7 hospitals in China from January 2004 to January 2016 were analyzed. A nomogram predicts survival was established to evaluate the effect of RMR through a decision curve.
Results
According to the RMR cut-off point (0.177), all patients were divided into Group L (RMR<0.177) (n = 179) and Group H (RMR ≥ 0.177) (n = 160). Patients with stage II and III disease with a high RMR who received AC had a significantly better 3-year OS than those who did not receive AC (P = 0.048 and 0.044), while AC had no significant effect on the survival of patients with low RMR. The independent prognostic factors for OS in patients with RGC who underwent AC were used to establish a nomogram. The C-index was 0.795, and the decision threshold was 0-85%. According to the nomogram, patients were divided into low-benefit patients with AC (point < 102 points) and high-benefit patients with AC (point ≥ 102 points).
Conclusions
The predictive model based on RMR in this study can provide a simple and accurate indication for postoperative AC in patients with RGC. It is recommended that postoperative AC be administered to high-benefit patients with a score of ≥102 on the nomogram.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
The authors.
Funding
Scientific and Technological Innovation Joint Capital Projects of Fujian Province.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
211P - The impact of low muscle mass to overall survival in bladder cancer patients undergoing chemotherapy: A systematic review and meta-analysis
Presenter: Karunia Japar
Session: e-Poster Display Session
212P - Stage I non-seminoma testicular cancer: Adjuvant management and outcomes
Presenter: Gaik Tin Quah
Session: e-Poster Display Session
213P - Stage I seminoma testicular cancer: Predictors of relapse and outcomes for adjuvant carboplatin vs active surveillance
Presenter: Gaik Tin Quah
Session: e-Poster Display Session
214P - Study of treatment outcome in adults with TFE related RCC
Presenter: Ajaykumar Singh
Session: e-Poster Display Session
215P - Analysis of spatial heterogeneity of responses in metastatic sites with nivolumab in renal cell carcinoma
Presenter: Venkata Pradeep Babu Koyyala
Session: e-Poster Display Session
216P - Clinical profile and treatment outcome of testicular seminoma treated at tertiary care centre in Chennai
Presenter: Sivasubramaniam Kumaravelu
Session: e-Poster Display Session
220P - A cost-effectiveness analysis of systemic therapy for metastatic hormone-sensitive prostate cancer
Presenter: Winnie Sung
Session: e-Poster Display Session
221P - Patient-reported sexual and urinary function in nonmetastatic castration-resistant prostate cancer (nmCRPC) when treated with apalutamide (APA) vs placebo (PBO) and ongoing androgen deprivation therapy (ADT) in SPARTAN
Presenter: Hiroji Uemura
Session: e-Poster Display Session
222P - Tolerability and treatment response to darolutamide (DARO) in patients with non-metastatic castration-resistant prostate cancer (nmCRPC) in the phase III ARAMIS trial
Presenter: Matthew R. Smith
Session: e-Poster Display Session
223P - Overall survival (OS) results of phase III ARAMIS study of darolutamide (DARO) added to androgen deprivation therapy (ADT) for non-metastatic castration-resistant prostate cancer (nmCRPC)
Presenter: Karim Fizazi
Session: e-Poster Display Session